DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $159,025,685 | +11.6% | 640,975 | +8.0% | 0.43% | +12.1% |
Q2 2023 | $142,444,833 | +98837.2% | 593,545 | +3.9% | 0.38% | -8.9% |
Q1 2023 | $143,975 | +9.6% | 571,283 | +15.4% | 0.42% | -0.9% |
Q4 2022 | $131,398 | -99.9% | 495,048 | +4.4% | 0.42% | -13.7% |
Q3 2022 | $122,456,000 | +8.3% | 474,073 | +6.3% | 0.49% | +5.4% |
Q2 2022 | $113,053,000 | -2.2% | 445,936 | +13.2% | 0.46% | +6.4% |
Q1 2022 | $115,555,000 | +5.1% | 393,935 | +17.8% | 0.44% | -6.2% |
Q4 2021 | $109,997,000 | +42.0% | 334,328 | +31.4% | 0.46% | +15.1% |
Q3 2021 | $77,469,000 | +21.0% | 254,463 | +6.7% | 0.40% | +1.8% |
Q2 2021 | $64,008,000 | +26.5% | 238,511 | +6.1% | 0.40% | +12.5% |
Q1 2021 | $50,608,000 | +14.9% | 224,845 | +13.4% | 0.35% | +4.4% |
Q4 2020 | $44,055,000 | +19.8% | 198,320 | +16.1% | 0.34% | -2.3% |
Q3 2020 | $36,787,000 | +31.3% | 170,844 | +7.8% | 0.35% | +23.1% |
Q2 2020 | $28,024,000 | +48.1% | 158,478 | +16.0% | 0.28% | +19.1% |
Q1 2020 | $18,920,000 | +32.3% | 136,674 | +46.6% | 0.24% | +58.4% |
Q4 2019 | $14,304,000 | +6.5% | 93,200 | +0.2% | 0.15% | -7.5% |
Q3 2019 | $13,432,000 | +0.7% | 93,000 | -0.4% | 0.16% | +1.3% |
Q2 2019 | $13,343,000 | +437.8% | 93,363 | +1.5% | 0.16% | +354.3% |
Q1 2019 | $2,481,000 | +37.0% | 91,975 | +422.5% | 0.04% | +9.4% |
Q4 2018 | $1,811,000 | +58.4% | 17,604 | +67.4% | 0.03% | +10.3% |
Q3 2018 | $1,143,000 | +17.2% | 10,519 | +6.4% | 0.03% | +3.6% |
Q2 2018 | $975,000 | +18.3% | 9,882 | +17.4% | 0.03% | -6.7% |
Q1 2018 | $824,000 | +14.4% | 8,417 | +8.5% | 0.03% | +7.1% |
Q4 2017 | $720,000 | -12.2% | 7,755 | -18.9% | 0.03% | -24.3% |
Q3 2017 | $820,000 | +9.5% | 9,559 | +7.7% | 0.04% | +5.7% |
Q2 2017 | $749,000 | +1.8% | 8,873 | +3.1% | 0.04% | +9.4% |
Q1 2017 | $736,000 | +72.4% | 8,603 | +57.0% | 0.03% | +60.0% |
Q4 2016 | $427,000 | -37.8% | 5,480 | -37.3% | 0.02% | -39.4% |
Q3 2016 | $686,000 | +28.0% | 8,737 | +64.4% | 0.03% | +13.8% |
Q2 2016 | $536,000 | -22.4% | 5,313 | -34.4% | 0.03% | -6.5% |
Q3 2015 | $691,000 | +233.8% | 8,104 | +208.1% | 0.03% | +34.8% |
Q2 2014 | $207,000 | +1.0% | 2,630 | -3.6% | 0.02% | -11.5% |
Q1 2014 | $205,000 | -65.1% | 2,729 | -64.1% | 0.03% | -64.9% |
Q4 2013 | $587,000 | +17.2% | 7,603 | +5.2% | 0.07% | -19.6% |
Q3 2013 | $501,000 | – | 7,228 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |